Transition from Asymptomatic to Symptomatic Systolic Chronic Heart Failure: Rationale and Design of TransitionCHF
ESC Heart Failure · 2024
DOI: 10.1002/ehf2.14783 ↗Kurz gefasst
Fachartikel in der Zeitschrift ESC Heart Failure, 2024. Verfasst von Anja Sandek und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinic for Cardiology and Pneumology, Heart Research Center, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Germany. Hauptthemen laut MEDLINE: Asymptomatic Diseases, Disease Progression, Heart Failure, Systolic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: German Ministry of Education and Research.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Aims
Chronic systolic heart failure (CHF) is a major health burden. A relevant number of patients shows asymptomatic left ventricular dysfunction (ALVSD) before symptomatic CHF or becomes asymptomatic after initiating heart failure therapy. Clinical course, prognosis, and response to pharmacological and device-based treatment are largely unknown in these two distinct groups of patients. Current pharmacological and interventional therapies do neither properly address the underlying pathophysiology nor prevent malignant loss of function. New therapeutic paradigms are needed to stop the progression from asymptomatic to symptomatic heart failure. Key questions are what causes progression of clinically asymptomatic New York Heart Association (NYHA) I heart failure to overt heart failure (>NYHA I) in some but not all patients and the underlying reasons for this transition. This requires the identification of disease mechanisms and biomarkers that predict outcome in well-defined cohorts for innovative preclinical and clinical trials. Methods and results TransitionCHF is a prospective, multicentre, longitudinal pathophysiological evaluation cohort study in patients with asymptomatic systolic dysfunction NYHA I and left ventricular ejection fraction ≤40%. The cohort comprises both incidental findings and patients who had become asymptomatic after a previous symptomatic event. TransitionCHF has recruited 1000 patients with ALVSD caused by various aetiologies in 20 university heart failure clinics across Germany. Both patients with and without comorbidities at study entry will be recruited. Patients will be systematically investigated and followed up annually over the course of the study. The primary composite endpoint is time to hospitalization for heart failure and cardiovascular death. The secondary endpoints assess time to all-cause mortality, to cardiovascular mortality, to heart failure mortality, to all-cause hospitalization, to heart failure hospitalization, and to recurrent heart failure hospitalizations, as well as time to assist device implantation/transplantation. Additional investigations focusing on biomarkers, comorbidities, gender aspects, nutrition, and functional parameters including quality of life will be performed.
Conclusions
TransitionCHF will provide a more thorough pathophysiological understanding of the progression of asymptomatic systolic dysfunction into symptomatic heart failure that will help develop therapies tailored to prevent progressive heart failure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinic for Cardiology and Pneumology, Heart Research Center, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Germany.
- German Centre for Cardiovascular Research (DZHK), Göttingen, Germany.
- Department of Internal Medicine and Cardiology, German Heart Center Charité, Charité-University Medicine Berlin, Berlin, Germany.
- German Centre for Cardiovascular Research (DZHK), Berlin, Germany.
- Department of Medical Statistics, University Medical Center Göttingen, Göttingen, Germany.
- Clinic and Policlinic for Cardiology, University Hospital Leipzig, Leipzig, Germany.
Förderung
- German Ministry of Education and Research
Zitieren
APA
Sandek, A., Edelmann, F., Gertler, C., Friede, T., Wachter, R., Hasenfuß, G., & TransitionCHF consortium (2024). Transition from Asymptomatic to Symptomatic Systolic Chronic Heart Failure: Rationale and Design of TransitionCHF. ESC Heart Failure. https://doi.org/10.1002/ehf2.14783
Vancouver
Sandek A, Edelmann F, Gertler C, Friede T, Wachter R, Hasenfuß G, et al. Transition from Asymptomatic to Symptomatic Systolic Chronic Heart Failure: Rationale and Design of TransitionCHF. ESC Heart Failure. 2024. doi:10.1002/ehf2.14783
BibTeX
@article{Sandek2024,
author = {Sandek, Anja and Edelmann, Frank and Gertler, Christoph and Friede, Tim and Wachter, Rolf and Hasenfuß, Gerd and TransitionCHF consortium, TransitionCHF consortium},
title = {Transition from Asymptomatic to Symptomatic Systolic Chronic Heart Failure: Rationale and Design of TransitionCHF},
journal = {ESC Heart Failure},
year = {2024},
doi = {10.1002/ehf2.14783}
}
EUVIMED